Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases

NCT01763385 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

210

Enrollment

OTHER

Sponsor class

Conditions

Non-small-cell Lung Cancer
Brain Metastases

Interventions

DRUG: Erlotinib
RADIATION: concurrent brain radiotherapy
RADIATION: secondary brain radiotherapy

Sponsor

Wu Jieping Medical Foundation

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]